We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: B-cell lymphoma
MedXY News
EnglishTag

B-cell lymphoma

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Breaking Ferroptosis Resistance: PRMT5 Inhibition Emerges as a Game-Changer in B-Cell Lymphoma Therapy
Hematology-OncologyB-cell lymphomaferroptosis

Breaking Ferroptosis Resistance: PRMT5 Inhibition Emerges as a Game-Changer in B-Cell Lymphoma Therapy

By MedXY|Apr 21, 2026

PRMT5 inhibition sensitizes B-cell lymphomas to ferroptosis by disrupting the PRMT5-ATF5-SLC7A11 axis, offering a novel therapeutic strategy for relapsed or refractory disease.

Clinical Evolution of Axicabtagene Ciloleucel: From Salvage Therapy to Second-Line Standard of Care
Clinical Updatesaxicabtagene ciloleucelB-cell lymphoma

Clinical Evolution of Axicabtagene Ciloleucel: From Salvage Therapy to Second-Line Standard of Care

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
By MedXY|Jan 13, 2026

This review synthesizes clinical trial evidence for Axicabtagene Ciloleucel, tracing its development from refractory B-cell lymphoma to its current role as a second-line standard and its expansion into indolent and mantle cell lymphomas.

T-ICAHT: A New Grading System for Thrombocytopenia After CAR T-cell Therapy with Prognostic Significance
Hematology-OncologyB-cell lymphomaCAR T-cell therapy

T-ICAHT: A New Grading System for Thrombocytopenia After CAR T-cell Therapy with Prognostic Significance

By MedXY|Oct 5, 2025

A novel grading system, T-ICAHT, quantifies thrombocytopenia after CAR T-cell therapy, revealing its prevalence and prognostic impact, highlighting its value in patient management and outcome prediction across hematologic malignancies.

Off-the-Shelf iPSC-Derived Natural Killer Cell Therapy for Relapsed or Refractory B-Cell Lymphoma: Key Evidence from a Multicentre Phase 1 Study
Clinical UpdatesB-cell lymphoma

Off-the-Shelf iPSC-Derived Natural Killer Cell Therapy for Relapsed or Refractory B-Cell Lymphoma: Key Evidence from a Multicentre Phase 1 Study

By MedXY|Oct 1, 2025

FT516, an iPSC-derived NK cell therapy, shows promising safety and efficacy in relapsed or refractory B-cell lymphoma, potentially overcoming key limitations of existing cell therapies.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities